Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 25, 2020

Primary Completion Date

April 29, 2022

Study Completion Date

April 29, 2022

Conditions

COVID-19 Infection

Interventions

DRUG

Zavegepant (BHV-3500)

10 mg intranasal (IN) for 14 days

DRUG

Placebo

Placebo Q8h for 14 days

Trial Locations (6)

Thomas Jefferson University Hospital, Philadelphia

Jefferson Torresdale Hospital, Philadelphia

Georgetown University Hospital Research Pharmacy, Washington D.C.

Georgetown University Hospital, Washington D.C.

Georgetown University Medical Center, Washington D.C.

Roper Hospital, Charleston